Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Biotechnology

Healthcare
$0.84 -2.80%

-$0.04 today

Market cap
$212.10M
Beta
1.51
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.85High $2.09

Volume 1.22M

Average 1.19M

LCTX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Lineage Cell Therapeutics, Inc.AMEX: LCTX

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit grows, but more slowly than its trailing trend

Q1 FY2026 gross profit of $1.54M rose 4.8% year over year, behind the +56.0% change in trailing-twelve-month gross profit. Sequentially, it fell 76.5% from the prior quarter. Over 3 fiscal years it compounded at -0.6% a year.

Context

  • Gross profit amounted to 94.2% of revenue in FY2025, down 2.3 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +4.8% toward the trailing-twelve-month pace of +56.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.54M-76.5% QoQ
Last fiscal yearDec 2025
$13.71M+49.6% YoY
LTMMar 2026
$14.48M+56.0% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.8%——
1 year+49.6%——
3-year CAGR-0.6%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
13.71M USD
Year-over-year change
+49.6%
4-year CAGR
+53.5%

Gross Profit vs competitors

How LCTX compares with its peers on the latest reported figures

  • LCTX's LTM Mar 2026 gross profit of $14.48M is the 3rd highest of the 4 companies compared; the peer median is $20.19M.
  • Its year-over-year change of +56.0% is the 2nd highest of 4, against a peer median of -48.5%.
  • Gross profit amounts to 98.0% of revenue for LCTX, versus a peer median of 78.0%.
LCTX Competitors Peer median
Gross Profit for LCTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MESOMesoblast LimitedLTM Jun 2026$96.22M +368.3%—80.0%
CELUCelularity Inc.LTM Dec 2025$20.19M -48.5%—76.0%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$14.48M +56.0%-0.6%98.0%
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$29.86M -126.0%+164.4%—
Peer median (excluding LCTX) $20.19M-48.5%+164.4%78.0%

Competitors are the stored peer set for LCTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.9M14.7M8.95M9.5M14.56M
Cost of Revenue1.43M728K671K334K845K
Gross Profit2.47M13.98M8.27M9.17M13.71M
Gross Margin63.4%95.0%92.5%96.5%94.2%
Research & Development33.91M13.99M15.71M12.47M17.73M
Selling, General & Admin18.21M22.51M17.3M18.17M18.46M
Operating Expenses51.68M36.5M33.01M30.64M35.49M
Depreciation & Amortization873K727K692K609K699K
EBITDA(42.4M)(25.09M)(22.59M)(17.97M)(67.95M)
EBITDA Margin-1088.2%-170.6%-252.5%-189.2%-466.8%
Operating Income(49.21M)(22.52M)(24.73M)(21.48M)(21.78M)
Operating Margin-1263.1%-153.2%-276.5%-226.1%-149.6%
Interest Income2K829K1.63M1.72M1.69M
Interest Expense00000
Other Income / Expenses5.94M(3.29M)1.45M2.9M(46.87M)
Income Before Tax(43.27M)(25.81M)(23.28M)(18.58M)(68.65M)
Pre-Tax Margin-1110.6%-175.6%-260.3%-195.6%-471.6%
Income Tax Expense0541K(1.8M)0(5.11M)
Net Income(43.02M)(26.27M)(21.49M)(18.61M)(63.53M)
Net Margin-1104.2%-178.7%-240.2%-195.9%-436.5%
EPS (Basic)(0.26)(0.15)(0.12)(0.09)(0.28)
EPS (Diluted)(0.26)(0.15)(0.12)(0.09)(0.28)
Weighted Avg Shares164.5M169.79M172.66M200.19M230.12M
Weighted Avg Shares (Diluted)164.5M169.79M172.66M200.19M230.12M

Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.